DICE: An international study to assess the effectiveness of TAK228 in combination with weekly paclitaxel, compared with weekly paclitaxel on its own, in women with advanced/recurrent ovarian, fallopian tube or primary peritoneal cancer that is resistant to platinum-based chemotherapy
- Conditions
- Ovarian, fallopian tube or primary peritoneal cancer of clear cell, endometrioid or high grade serous subtype or carcinosarcomaMedDRA version: 20.0 Level: PT Classification code 10033128 Term: Ovarian cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10052171 Term: Peritoneal carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10016180 Term: Fallopian tube cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2016-000065-23-GB
- Lead Sponsor
- Imperial College London
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- Not specified
- Target Recruitment
- 126
1. Able to understand and willing to sign informed consent form prior to initiation of any study procedures
2. Females = 18 years of age
3. Pathological diagnosis of ovarian, fallopian tube or primary peritoneal cancer, of clear cell, endometrioid or high grade serous subtype or carcinosarcoma. Local tumour board/MDT histological review is required and in mixed tumours more than 50% endometrioid, clear cell or high grade serous elements are required to define the predominant histology
4. Platinum-resistant disease (recurrence within 6 months of last platinum treatment), patients having received at least one prior line of chemotherapy. Carboplatin and weekly paclitaxel are permitted as first line therapy
5. Measurable disease as per Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 by CT or MRI
6. Fresh tumour biopsy during screening is compulsory if judged technically feasible by radiologist
7. Patients with a history of brain metastasis are eligible as long as all the following criteria are met: brain metastases must have been treated, have no evidence of progression or haemorrhage after treatment, have been off dexamethasone for 4 weeks prior to first study treatment, and no ongoing requirement for dexamethasone or anti-epileptic drugs
8. Available blocks for (IHC) and tissue microarray (TMA) or, if no block is available, 20 ordinary unstained slides (5µm sections) will be acceptable
9. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2
10. Adequate organ and bone marrow function
11. Patients who:
a. Are postmenopausal for > 1 year before the screening visit OR
b. Are surgically sterile OR
c. If of childbearing potential, patient agrees to practice one of the following from informed consent to 90 days after the last dose of study treatment (or longer, as mandated by local labelling [e.g. Summary of Product Characteristics]):
i. Practice 1 highly effective method of contraception and 1 additional effective barrier method at the same time OR
ii. Practice true abstinence where this is in line with the preferred and usual lifestyle of the patient
12. For women of child-bearing potential, negative blood serum pregnancy test within 14 days prior to the first study treatment
13. Able to swallow oral medication
Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 40
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 86
1. Previous treatment with PI3K, AKT, dual PI3K/mTOR inhibitors, mTORC1/2 inhibitors or mTORC1 inhibitors
2. Prior weekly single agent paclitaxel
3. Central nervous system (CNS) metastasis, for patients who have brain metastases, they will be eligible if their brain metastases must have been treated, have no evidence of progression or haemorrhage after treatment, have been off dexamethasone for 4 weeks prior to first study drug administration, and no ongoing requirement for dexamethasone or anti-epileptic drugs
4. Other clinically significant co-morbidities, such as uncontrolled pulmonary disease, active central nervous system disease, active infection, or any other condition that could compromise the patient’s participation in the study
5. Known human immunodeficiency virus infection
6. Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection
7. Any serious medical or psychiatric illness that could, in the investigator’s opinion, potentially interfere with the completion of treatment according to this protocol
8. Diagnosed or treated for another malignancy within 2 years before administration of the first dose of study treatment, or previously diagnosed with another malignancy and evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection
9. Breast feeding or pregnant
10. Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of TAK228. In addition, patients with enteric stomata are also excluded
11. Treatment with any investigational products, chemotherapy or radiotherapy within 28 days, or major surgery within 21 days of study treatment
12. History of any of the following within the last 6 months before administration of the first dose of study treatment:
a. Ischemic myocardial event, including angina requiring therapy and artery revascularisation procedures
b. Ischemic cerebrovascular event, including transient ischemic attack and artery revascularisation procedures
c. Requirement for inotropic support (excluding digoxin) or serious (uncontrolled) cardiac arrhythmia (including atrial flutter/fibrillation, ventricular fibrillation or ventricular tachycardia)
d. Placement of a pacemaker for control of rhythm
e. New York Heart Association (NYHA) Class III or IV heart failure
f. Pulmonary embolism
13. Significant active cardiovascular or pulmonary disease including:
a. Uncontrolled hypertension (i.e., systolic blood pressure > 180 mm Hg, diastolic blood pressure > 95 mm Hg). Use of anti-hypertensive agents to control hypertension before first dose of study treatment is allowed.
b. Pulmonary hypertension
c. Uncontrolled asthma or O2 saturation < 90% by arterial blood gas analysis or pulse oximetry on room air
d. Significant valvular disease; severe regurgitation or stenosis by imaging independent of symptom control with medical intervention, or history of valve replacement
e. Medically significant (symptomatic) bradycardia
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method